Granules India Ltd is up for a third straight session today. The stock is quoting at Rs 572.65, up 2.52% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.13% on the day, quoting at 25777.65. The Sensex is at 84211.69, down 0.1%. Granules India Ltd has slipped around 16.26% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has slipped around 0.65% in last one month and is currently quoting at 23281.2, down 0.62% on the day. The volume in the stock stood at 40.39 lakh shares today, compared to the daily average of 63.92 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 580.55, up 3.06% on the day. Granules India Ltd is up 60.7% in last one year as compared to a 32% jump in NIFTY and a 51.41% jump in the Nifty Pharma index.The PE of the stock is 30.08 based on TTM earnings ending June 24.Powered by Capital Market - Live

Granules India unveiled its Mobile Cancer Screening Unit at AIG Hospitals. This initiative, spearheaded by the Granules Trust in partnership with Asian Medical Foundation, UC Breast Foundation and AIG Hospitals aims to enhance cancer detection and treatment in underserved communities. The state-of-the-art mobile unit Breast Health Express, brings advanced medical technology directly to communities in need. Equipped with cutting-edge mammography and ultrasound capabilities, as well as facilities for essential health checks such as haemoglobin, blood pressure, and glucose levels, this mobile clinic marks a major advancement in equitable and accessible healthcare. By offering these critical services and free medicine distribution, the initiative seeks to revolutionize cancer screening, with a particular emphasis on early breast cancer detection. Timed to coincide with Breast Cancer Awareness Month in October, the Breast Health Express aligns seamlessly with the global focus on breast cancer prevention and early detection. The mobile unit is set to commence operations in and around Hyderabad, with plans to expand to additional districts of Telangana in the coming monthsPowered by Capital Market - Live

Granules India Ltd fell for a fifth straight session today. The stock is quoting at Rs 549.15, down 0.14% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.13% on the day, quoting at 25417.95. The Sensex is at 83067.63, up 0.1%.Granules India Ltd has lost around 17.25% in last one month.Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has increased around 5.37% in last one month and is currently quoting at 23448.75, down 0.07% on the day. The volume in the stock stood at 21.73 lakh shares today, compared to the daily average of 53.17 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 550.05, down 0.05% on the day. Granules India Ltd jumped 67.99% in last one year as compared to a 26.25% rally in NIFTY and a 51.14% spurt in the Nifty Pharma index.The PE of the stock is 29.64 based on TTM earnings ending June 24.Powered by Capital Market - Live

Granules India announced the completion of USFDA inspection of its Gagillapur FD facility with six observations. The inspection was conducted from 26 August 2024 to 06 September 2024. Powered by Capital Market - Live

'We acknowledge that several investors have sought clarification, and we want to reassure them that we are actively addressing the observations and are fully committed to resolving the issues raised. We will work with the USFDA to address the issues raised in the observations,' the company stated in regulatory filing. On 7 September 2024, the company announced the completion of the US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The inspection was conducted from 26th August to 6th September 2024, concluded with six observations. The inspection covered both current good manufacturing practice (cGMP) and pre-approval inspection (PAI) processes. Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24. Revenue from operations in first quarter of FY25 was at Rs 1,179.87 crore, up 19.72% from Rs 985.52 crore reported in the same period a year ago.Powered by Capital Market - Live

Prism Johnson Ltd, R R Kabel Ltd, TCI Express Ltd and Raymond Ltd are among the other losers in the BSE's 'A' group today, 12 September 2024.Granules India Ltd tumbled 16.63% to Rs 565.1 at 14:45 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 12.65 lakh shares were traded on the counter so far as against the average daily volumes of 54447 shares in the past one month.Prism Johnson Ltd crashed 5.37% to Rs 219.2. The stock was the second biggest loser in 'A' group.On the BSE, 3.99 lakh shares were traded on the counter so far as against the average daily volumes of 2.73 lakh shares in the past one month.R R Kabel Ltd lost 3.68% to Rs 1651.05. The stock was the third biggest loser in 'A' group.On the BSE, 17013 shares were traded on the counter so far as against the average daily volumes of 8881 shares in the past one month.TCI Express Ltd slipped 3.66% to Rs 1093.75. The stock was the fourth biggest loser in 'A' group.On the BSE, 5795 shares were traded on the counter so far as against the average daily volumes of 5015 shares in the past one month.Raymond Ltd dropped 3.24% to Rs 1852.5. The stock was the fifth biggest loser in 'A' group.On the BSE, 27586 shares were traded on the counter so far as against the average daily volumes of 46186 shares in the past one month.Powered by Capital Market - Live

Granules India Ltd rose for a third straight session today. The stock is quoting at Rs 686.45, up 1.63% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Granules India Ltd has added around 32.57% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has added around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 8.52 lakh shares today, compared to the daily average of 26.57 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 688, up 1.63% on the day. Granules India Ltd is up 132.26% in last one year as compared to a 27.49% gain in NIFTY and a 47.43% gain in the Nifty Pharma index.The PE of the stock is 36.39 based on TTM earnings ending June 24.Powered by Capital Market - Live

Granules India announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Oral Solution 1mg/5mL filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company. It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution, 1 mg/5 mL of Merz Pharmaceuticals, LLC. Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients aged three to 16 years who have neurological conditions associated with problem drooling.Powered by Capital Market - Live

The ANDA has been filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company. It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution of Merz Pharmaceuticals, LLC. Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients aged three to 16 years who have neurological conditions associated with problem drooling. Krishna Prasad Chigurupati, chairman and managing director of Granules India said, 'As we strengthen Granules' footprint in the U.S. market, this approval highlights our robust quality systems, ensuring compliance with the highest regulatory standards.' Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24. Revenue from operations in first quarter of FY25 was at Rs 1,179.87 crore, up 19.72% from Rs 985.52 crore reported in the same period a year ago. Powered by Capital Market - Live

It is bioequivalent and therapeutically equivalent to the reference listed drug Desyrel Tablets of Pragma Pharmaceuticals, LLC. Trazodone tablets are indicated for the treatment of major depressive disorder in adults. The current annual U.S. market for Trazodone tablets is approximately $128 Million, according to MAT Jun 2024, IQVIA/IMS Health. Dr. Krishna Prasad Chigurupati, chairman and managing director, Granules India, said: 'We have received the approval within 10 months of filing the application, which is a testament to our strong R&D capabilities. The product will be launched within this quarter and the market share will grow steadily over the next few quarters.' Granules now has 65 ANDA approvals from the US FDA (64 final approvals and 1 tentative approval). Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24. Revenue from operations in first quarter of FY25 was at Rs 1,179.87 crore, up 19.72% from Rs 985.52 crore reported in the same period a year ago. The scrip rose 0.90% to currently trade at Rs 658.30 on the BSE. Powered by Capital Market - Live